Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94362 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL94822 | 0.79 | — | — | |
| SCHEMBL3916442 | 0.79 | ADORA1 (0.30) | ADORA2A | |
| SCHEMBL4002943 | 0.77 | CSNK2A2 (0.35) | ADORA2AMAPT | |
| SCHEMBL16513155 | 0.74 | ADORA2A (0.33) | ADORA2AMAPT | |
| SCHEMBL5133268 | 0.74 | CSNK2A2 (0.35) | ADORA2AMAPT | |
| SCHEMBL30819131 | 0.74 | PIK3CG (0.33) | ADORA2AMAPTEGFRFLT3 | |
| SCHEMBL4907122 | 0.74 | PIK3CG (0.33) | ADORA2AMAPTEGFRFLT3 | |
| SCHEMBL2953678 | 0.74 | ADORA3 (0.38) | ADORA2A | |
| Water SCHEMBL8757459 | 0.72 | DHFR (0.33) | ADORA2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112745670-A | Glass fiber composite material and preparation method thereof | 泗县绿昂新材料科技有限公司 | 2021-05-04 | — | — | CN | claimed |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| US-11673136-B2 | Nanopore devices for sensing biomolecules | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021263194-A1 | INHIBITION OF N-GLYCOSYLATED GRP94 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021263194-A1 | INHIBITION OF N-GLYCOSYLATED GRP94 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210323965-A1 | SMALL-MOLECULE HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2021-10-21 | — | — | US | disclosed |
| CN-112745670-A | Glass fiber composite material and preparation method thereof | 泗县绿昂新材料科技有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. | 2001-07-19 | — | — | US | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-6087482-A | INTER-SUGAR LINKAGES ARE FOUR ATOM LINKING GROUPS; FOR IMPROVED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5677437-A | MACROMOLECULES; REGULATING RNA EXPRESSION; THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0655088-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993008296-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | ADORA2A 1036/4885MAPT 4125/4885EGFR 4255/4885 |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | ADORA2A 3584/4885MAPT 3845/4885EGFR 1901/4885 |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | GRPR, HSPB1, HSP90AB2P | ADORA2A 3509/4885MAPT 4478/4885EGFR 391/4885 |
| US-20210323965-A1 | SMALL-MOLECULE HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | ADORA2A 1290/4885MAPT 1997/4885EGFR 2481/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | ADORA2A 3584/4885MAPT 3845/4885EGFR 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.